US4950483A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Collagen wound healing matrices and process for their production
Assignee: Surgical Specialties US Corp
•
Filing: 1988-12-16
•
Granted: 1990-08-21
•
Expires: 2008-12-16
Abstract
Abstract Collagen implants that are useful as wound healing matrices are characterized by being formed of collagen fibrils that are not chemically cross-linked, and having a bulk density of 0.01 to 0.3 g/cm 3 and a pore population in which at least about 80% of the pores have an average pore size of 35 to 250 microns. The implants are capable of promoting connective tissue deposition, angiogenesis, reepithelialization, and fibroplasia. The wound healing matrix also serves an an effective sustained delivery system for synergistic combinations of FGF and TGF-B.
Inventors
- 👤 George Ksander
- 👤 Yasushi Ogawa
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-22 22:32
CPC Classifications
A; A61; A61L; A61L27/00; A61L27/50; A61L27/54; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/39; A61L27/14; A61L27/22; A61L27/24; A61P; A61P17/00; A61P35/00; A61P37/00; A61P43/00; A61P7/00; A61F; A61F2310/00; A61F2310/00005; A61F2310/00365; A61L2300/00; A61L2300/20; A61L2300/25; A61L2300/252; A61L2300/40; A61L2300/412; A61L2300/414; A61L2300/426; A61L2300/45; Y; Y10; Y10S; Y10S128/00; Y10S128/08; Y10S623/00; Y10S623/924
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
71 words
A collagen sponge composition, comprising: a matrix having a density of about 0.01 to about 0.3 g/cm 3 , a thickness of about 1-20 mm, and having pores at least 80% of which are at least 35 um in diameter, wherein said matrix comprises fibrillar atelopeptide collagen, wherein said fibrils are about 50-200 nm in diameter, and are not chemically cross-linked; and a synergistic wound-healing effective amount of TGF-B and FGF.
Claim 2
Dependent Claim
71 words
A collagen sponge composition, comprising: a matrix having a density of about 0.01 to about 0.3 g/cm 3 , a thickness of about 1-20 mm, and having pores at least 80% of which are at least 35 um in diameter, wherein said matrix comprises fibrillar atelopeptide collagen, wherein said fibrils are about 50-200 nm in diameter, and are not chemically cross-linked; and a synergistic wound-healing effective amount of TGF-B and FGF.
Claim 3
Dependent Claim
22 words
The sponge composition of claim 1 which further comprises heparin in a concentration of between about 5 ug/mL and about 500 ug/mL.
Claim 4
Dependent Claim
28 words
The sponge composition of claim 1 wherein said synergistic wound-healing effective amount of TGF-B and FGF is about 0.07 to about 200 ug per cm 2 of composition.
Claim 5
Dependent Claim
13 words
The sponge composition of claim 3 wherein said TGF-B is native bovine TGF-B2.
Claim 6
Dependent Claim
13 words
The sponge composition of claim 3 wherein said FGF is recombinant human aFGF.
Claim 7
Independent Claim
87 words
A method for promoting wound healing in a mammal having a wound, which method comprises: applying to said wound a collagen sponge composition having a density of about 0.01 to about 0.3 g/cm 3 , a thickness of about 1-20 mm, and having pores at least 80% of which are at least 35 um in diameter, wherein said matrix comprises fibrillar atelopeptide collagen, wherein said fibrils are about 50-200 nm in diameter, and are not chemically cross-linked; and a synergistic wound-healing effective amount of TGF-B and FGF.
Claim 8
Independent Claim
87 words
A method for promoting wound healing in a mammal having a wound, which method comprises: applying to said wound a collagen sponge composition having a density of about 0.01 to about 0.3 g/cm 3 , a thickness of about 1-20 mm, and having pores at least 80% of which are at least 35 um in diameter, wherein said matrix comprises fibrillar atelopeptide collagen, wherein said fibrils are about 50-200 nm in diameter, and are not chemically cross-linked; and a synergistic wound-healing effective amount of TGF-B and FGF.
Claim 9
Dependent Claim
24 words
The method of claim 6 wherein said sponge composition further comprises heparin in a concentration of between about 5 ug/mL and about 500 ug/mL.
Claim 10
Dependent Claim
27 words
The method of claim 6 wherein said synergistic wound-healing effective amount of TGF-B and FGF is about 0.07 to about 200 ug per cm 2 of composition.
Claim 11
Dependent Claim
12 words
The method of claim 8 wherein said TGF-B is native bovine TGF-B2.
Claim 12
Dependent Claim
12 words
The method of claim 8 wherein said FGF is recombinant human aFGF.
References Cited (Backward Citations)
US3742955A
Cited
US3810473A
Cited
US4238480A
Cited
US4390519A
Cited
US4404970A
Cited
US4279812A
Cited
US4412947A
Cited
US4320201A
Cited
US4415628A
Cited
US4578067A
Cited
US4544516A
Cited
US4515637A
Cited
WO1985004412A1
Cited
US4789663A
Cited
US4553974A
Cited
US4557764A
Cited
US4725671A
Cited
US4795467A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-08-20 | 1994-02-19 | 1994-08-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-08-20 | 1998-02-19 | 1998-08-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-08-20 | 2002-02-19 | 2002-08-21 | $7700.00 | Window Closed / Lapsed |